Signifor
ApprovedSmall molecule
Signifor is one of 62 small molecule programs targeting Desmoplastic Small Round Cell Tumor. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Hypoglycemia
#DrugCompanyPhaseTrials
1Proglycem
TevaApproved
Aldactone
PfizerApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Glucagon
XXeris Pharmaceuticals
Phase 3
Ilaris
NovartisPhase 3
Zegalogue
Zealand PharmaPhase 3
Jardiance
Boehringer IngelheimPhase 3
Sandostatin
Sun PharmaPhase 3
Glibenclamide
Novo NordiskPhase 3
MS Contin
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Signifor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- ZZealand University Hospital